[ad_1]
SEOUL, South Korea–(BUSINESS WIRE)–The International Vaccine Institute (IVI) announced on November 10th it signed a memorandum of understanding (MOU) with Lemonex, a company specializing in RNA gene therapy development, and agreed to seek cooperation in research and development. IVI and Lemonex have agreed to join forces to introduce DegradaBALL® drug delivery technology to the development of infectious disease vaccines and advance vaccine development by using IVI’s extensive expertise in all areas of vaccine development.
According to the MOU, Lemonex and IVI will seek to contribute to global public health through research and development cooperation with the view to develop vaccines that respond to infectious viruses and cater to the needs of developing countries, and through joint projects to achieve common goals.
The two organizations plan to utilize Lemonex’s expertise in vaccine development and drug delivery platform, and rapidly develop a safe and effective mRNA vaccine through mutual cooperation by using IVI’s extensive experience in clinical development and epidemiology.
Cheolhee Won, CEO of Lemonex, said, “We are proud to have established a vaccine R&D partnership with IVI to develop an mRNA vaccine. As people have had concern over potential adverse effects caused by the existing drug delivery systems and vaccine supply shortages revealed in the early stage of the pandemic. In this situation, we will focus on developing mRNA vaccines adopting our drug delivery platform, DegradaBALL®, which has addressed problems, and will contribute to the speedy development of a vaccine in response to the next pandemic.”
LEM-mR203, which is being developed by Lemonex, is an mRNA vaccine candidate against Covid-19. The mRNA vaccine uses DegradaBALL®, a next-generation drug delivery platform technology developed by Lemonex, in lieu of the existing lipid nanoparticles (LNP).
The mRNA vaccine adopting DegradaBALL® is designed to minimizes…
..
[ad_2]
